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Background: An association between large patent foramen ovale (LPFO) and migraine headache has been reported. Vasoactive or inflammatory 
mediators escaping pulmonary endothelial metabolism by entering systemic circulation through the PFO has been a postulated mechanism. We 
sought to test this link by measuring arterial and venous levels of a variety of inflammatory or vasoactive mediators in those with LPFO versus small 
or absent PFO (APFO).
methods: Patients ≤ 55 years of age undergoing clinically indicated left and right heart cardiac catheterization (CC) were enrolled. Subjects 
underwent saline contrast echo prior to CC. During CC, a blood sample was drawn after catheter discard from the pulmonary artery. Blood draw 
with discard was similarly performed from the left ventricle upon release of Valsalva. Samples were analyzed for serotonin, leukotriene B4, and a 
27-cytokine panel. Pulmonary artery and left ventricular levels of each analyte were measured, and a trans-pulmonary gradient (TPG) computed as 
arterial-venous concentration for each analyte. Results of subjects with APFO (≤ 5 left heart bubbles at rest or Valsalva) were compared to those with 
LPFO (≥ 20 left heart bubbles).
results: A total of 17 patients were enrolled, 8 with APFO, and 9 with LPFO. In those with LPFO, there were significantly increased LV levels of 
Platelet Derived Growth Factor (p=.025) and Interleukin-12 (p=.032) compared to APFO. However, when we compared the TPG between LPFO and 
APFO, there were no significant differences. Although Tumor Necrosis Factor levels were out of assay range (OOR) for many subjects, using discrete 
variables of Detectable and OOR, p= 0.082 by Exact Wilcoxon test for TPG was identified, stratified for LPFO and APFO.
conclusions: This is the first reported attempt at demonstrating a pathophysiologic link between PFO and migraine headache. Given individual 
variability in venous and arterial levels of mediators, TPG may be the most appropriate measurement, permitting each patient to serve as their own 
control. On that basis, no significant differences between LPFO and APFO were found for any mediator. However, the trend in Tissue Necrosis Factor 
warrants continued study.
